Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

111 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Primary anti-vascular endothelial growth factor (VEGF)-refractory metastatic renal cell carcinoma: clinical characteristics, risk factors, and subsequent therapy.
Heng DY, Mackenzie MJ, Vaishampayan UN, Bjarnason GA, Knox JJ, Tan MH, Wood L, Wang Y, Kollmannsberger C, North S, Donskov F, Rini BI, Choueiri TK. Heng DY, et al. Among authors: mackenzie mj. Ann Oncol. 2012 Jun;23(6):1549-55. doi: 10.1093/annonc/mdr533. Epub 2011 Nov 5. Ann Oncol. 2012. PMID: 22056973 Free PMC article.
Conditional survival of patients with metastatic renal-cell carcinoma treated with VEGF-targeted therapy: a population-based study.
Harshman LC, Xie W, Bjarnason GA, Knox JJ, MacKenzie M, Wood L, Srinivas S, Vaishampayan UN, Tan MH, Rha SY, Donskov F, Agarwal N, Kollmannsberger C, North S, Rini BI, Heng DY, Choueiri TK. Harshman LC, et al. Lancet Oncol. 2012 Sep;13(9):927-35. doi: 10.1016/S1470-2045(12)70285-1. Epub 2012 Aug 8. Lancet Oncol. 2012. PMID: 22877847 Free PMC article.
The association of clinical outcome to first-line VEGF-targeted therapy with clinical outcome to second-line VEGF-targeted therapy in metastatic renal cell carcinoma patients.
Al-Marrawi MY, Rini BI, Harshman LC, Bjarnason G, Wood L, Vaishampayan U, MacKenzie M, Knox JJ, Agarwal N, Al-Harbi H, Kollmannsberger C, Tan MH, Rha SY, Donskov FN, North S, Choueiri TK, Heng DY; International mRCC Database Consortium. Al-Marrawi MY, et al. Target Oncol. 2013 Sep;8(3):203-209. doi: 10.1007/s11523-012-0252-7. Epub 2013 Jan 9. Target Oncol. 2013. PMID: 23300029 Free PMC article.
External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study.
Heng DY, Xie W, Regan MM, Harshman LC, Bjarnason GA, Vaishampayan UN, Mackenzie M, Wood L, Donskov F, Tan MH, Rha SY, Agarwal N, Kollmannsberger C, Rini BI, Choueiri TK. Heng DY, et al. Lancet Oncol. 2013 Feb;14(2):141-8. doi: 10.1016/S1470-2045(12)70559-4. Epub 2013 Jan 9. Lancet Oncol. 2013. PMID: 23312463 Free PMC article.
Prognostic factors of survival for patients with metastatic renal cell carcinoma with brain metastases treated with targeted therapy: results from the international metastatic renal cell carcinoma database consortium.
Vickers MM, Al-Harbi H, Choueiri TK, Kollmannsberger C, North S, MacKenzie M, Knox JJ, Rini BI, Heng DY. Vickers MM, et al. Clin Genitourin Cancer. 2013 Sep;11(3):311-5. doi: 10.1016/j.clgc.2013.04.012. Epub 2013 May 15. Clin Genitourin Cancer. 2013. PMID: 23684422
Metastatic non-clear cell renal cell carcinoma treated with targeted therapy agents: characterization of survival outcome and application of the International mRCC Database Consortium criteria.
Kroeger N, Xie W, Lee JL, Bjarnason GA, Knox JJ, Mackenzie MJ, Wood L, Srinivas S, Vaishamayan UN, Rha SY, Pal SK, Yuasa T, Donskov F, Agarwal N, Kollmannsberger CK, Tan MH, North SA, Rini BI, Choueiri TK, Heng DY. Kroeger N, et al. Among authors: mackenzie mj. Cancer. 2013 Aug 15;119(16):2999-3006. doi: 10.1002/cncr.28151. Epub 2013 May 21. Cancer. 2013. PMID: 23696129 Free PMC article.
Survival outcome and treatment response of patients with late relapse from renal cell carcinoma in the era of targeted therapy.
Kroeger N, Choueiri TK, Lee JL, Bjarnason GA, Knox JJ, MacKenzie MJ, Wood L, Srinivas S, Vaishamayan UN, Rha SY, Pal SK, Yuasa T, Donskov F, Agarwal N, Tan MH, Bamias A, Kollmannsberger CK, North SA, Rini BI, Heng DY. Kroeger N, et al. Among authors: mackenzie mj. Eur Urol. 2014 Jun;65(6):1086-92. doi: 10.1016/j.eururo.2013.07.031. Epub 2013 Jul 30. Eur Urol. 2014. PMID: 23916693
Impact of bone and liver metastases on patients with renal cell carcinoma treated with targeted therapy.
McKay RR, Kroeger N, Xie W, Lee JL, Knox JJ, Bjarnason GA, MacKenzie MJ, Wood L, Srinivas S, Vaishampayan UN, Rha SY, Pal SK, Donskov F, Tantravahi SK, Rini BI, Heng DY, Choueiri TK. McKay RR, et al. Among authors: mackenzie mj. Eur Urol. 2014 Mar;65(3):577-84. doi: 10.1016/j.eururo.2013.08.012. Epub 2013 Aug 15. Eur Urol. 2014. PMID: 23962746 Free PMC article.
The impact of low serum sodium on treatment outcome of targeted therapy in metastatic renal cell carcinoma: results from the International Metastatic Renal Cell Cancer Database Consortium.
Schutz FA, Xie W, Donskov F, Sircar M, McDermott DF, Rini BI, Agarwal N, Pal SK, Srinivas S, Kollmannsberger C, North SA, Wood LA, Vaishampayan U, Tan MH, Mackenzie MJ, Lee JL, Rha SY, Yuasa T, Heng DY, Choueiri TK. Schutz FA, et al. Among authors: mackenzie mj. Eur Urol. 2014 Apr;65(4):723-30. doi: 10.1016/j.eururo.2013.10.013. Epub 2013 Oct 26. Eur Urol. 2014. PMID: 24184025 Free PMC article.
111 results